Compare RHI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | BEAM |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 1994 | 2019 |
| Metric | RHI | BEAM |
|---|---|---|
| Price | $22.78 | $25.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 16 |
| Target Price | $30.33 | ★ $49.13 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 10.41% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $5,378,506,000.00 | $24,000.00 |
| Revenue This Year | $1.57 | N/A |
| Revenue Next Year | $6.00 | $35.80 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $21.83 | $13.53 |
| 52 Week High | $55.24 | $36.44 |
| Indicator | RHI | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 44.27 |
| Support Level | $22.32 | $23.42 |
| Resistance Level | $28.11 | $29.06 |
| Average True Range (ATR) | 1.02 | 1.45 |
| MACD | -0.06 | -0.19 |
| Stochastic Oscillator | 28.57 | 24.55 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.